News Headlines Article

Stand Up To Cancer launches new industry-supported research program
Los Angeles Business Journal

The nonprofit Stand Up To Cancer is launching a program aimed at bringing new treatments to cancer patients that will supported by funds and materials from companies in the pharmaceutical, biotechnology, diagnostic and medical devices industries. Collaborators for the new charitable initiative, SU2C Catalyst, include Merck & Co. Inc.(NYSE: MRK), Bristol-Myers Squibb Co.(NYSE: BMY) and Genentech, which is owned by Roche Group.